Kayla Freeman, DNP, APRN, FNP-C

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.

A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).